Apellis Pharma reveals Phase 2 study data for APL-2 in AIHA patients
Author : Shikha Sinha | Published Date : 2019-06-17
Apellis Pharmaceuticals Inc. has reportedly announced the updated data from its key Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including warm antibody autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD).
Sources close to the matter informed that in the current PLAUDIT study, 13 patients with CAD have been recruited to get subcutaneous APL-2 treatment out of which 10 patients have been on APL-2 treatment for minimum 168 days. The clinical study has also registered 11 patients with wAIHA out of which 8 were Direct Antiglobulin Test C3+, while 5 of the C3+ wAIHA patients have been on APL-2 treatment for at least 168 days.
According to CMO of Apellis, Federico Grossi, patients with autoimmune hemolytic anemias on APL-2 treatment have apparently shown improvement both in quality of life scores and vital hematologic measures. These data would provide a clear path to move forward with a key Phase 3 clinical study of APL-2 in patients with CAD, which the company expects to commence in early 2020.
Seemingly, the company has also seen hematologic improvements in patients with wAIHA receiving treatment through APL-2 medication, when there is substantial involvement of the complement pathway. The company will continue to assess the potential of APL-2 treatment for patients with C3+ wAIHA, Grossi said.
Data from the PLAUDIT trial will be unveiled in an oral presentation at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, Netherlands. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company which is focused on the development of new therapeutic compounds for the treatment of the disease through the inhibition of the complement system.
Apparently, the data will be presented by Bruno Fattizzo, a Consultant Hematologist of Fondazione IRCCS Ca' Granda Policlinico Hospital in Milan, Italy. This trial reveals that APL-2 treatment has the potential to considerably help patients with autoimmune hemolytic anemias when there is complement involvement, Dr. Fattizzo mentioned.
Source credit: http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-presents-data-ongoing-apl-2-phase-2
About Author
Shikha Sinha . .
Shikha Sinha currently pens down content for fractovia.org, a news platform which provides the latest business highlights and industry trends. Shikha also is a contributor on various other online media websites where she writes informative, research-oriented content spanning the retail, healthcare, F&B, and technology sectors. As her first stint in writing, Shikha was an active contributor on Yahoo Voices where she penned down creative and imaginative pieces. She holds a Bachelor of Technology degree in Electrical and Electronics Engineering. She can be contacted at- [email protected] | https://twitter.com/shikhas999
Related News
Clio raises $250 million in a Series D funding by TCV and JMI Equity
The cloud-based legal technology startup hits a historic mark in future of legal industry with this investment. Clio, a leading legal software company has recently announced that it has bagged US$250 million in Series D funding from American equity firms JMI Equity and TCV. According to sour... Read More>>
Co-working firm Spacious the latest in WeWork’s acquisition spree
New York-based co-working business, The We Company, formerly known as WeWork, has today announced its acquisition of rival start-up Spacious. The company, formed three years ago, is focused on converting restaurants closed during the day into efficient spaces for co-working. WeWork is a part of many... Read More>>
SoftBank in talks to invest $150M in Dailyhunt and $400M in Lenskart
SoftBank is expected to lead a $250 million round with private equity major Carlyle for Dailyhunt South American conglomerate Synergy Group also hopes to invest in India’s Jet Airways. SoftBank Group Corp., a Japanese multinational conglomerate, is reportedly in talks to clo... Read More>>